Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT02477891 Approved for marketing - Multiple Myeloma Clinical Trials

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Start date: n/a
Phase:
Study type: Expanded Access

The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available or available through another protocol for subjects with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or whose disease is double refractory to both a PI and an IMiD.

NCT ID: NCT02368301 Approved for marketing - Multiple Myeloma Clinical Trials

Expanded Access Treatment Protocol CA204-143

Start date: n/a
Phase: N/A
Study type: Expanded Access

The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.

NCT ID: NCT01632826 Approved for marketing - Multiple Myeloma Clinical Trials

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

PEXIUS
Start date: n/a
Phase: N/A
Study type: Expanded Access

To provide pomalidomide access to relapsed/refractory multiple myeloma subjects with a likelihood of benefit from the pomalidomide treatment while the medication is not commercially available

NCT ID: NCT01410500 Approved for marketing - Multiple Myeloma Clinical Trials

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to expand upon the safety data for carfilzomib by providing expanded access to patients with relapsed and refractory multiple myeloma who are unable to enroll in any other ongoing carfilzomib trial.